Novel therapies in chronic lymphocytic leukemia: An update.
Lymphoma Hub5 Tammi 2023

Novel therapies in chronic lymphocytic leukemia: An update.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Chan Cheah, University of Western Australia, Perth, AU. We asked for an update on novel therapies in chronic lymphocytic leukemia (CLL).

Cheah reviews the abstracts that were presented at ASH on novel BTK inhibitors and Bcl-2 inhibitors for relapsed/refractory CLL. This includes an analysis of the potency, toxicity, and MRD response rates of the Bcl-2 inhibitor, BGB-11417, as well as the results of the phase I/II BRUIN study of the non-covalent BTK inhibitor, pirtobrutinib, in heavily pretreated patients with CLL and patients with Richter’s transformation.

Hosted on Acast. See acast.com/privacy for more information.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(53)

Symposium |Optimizing chronic lymphocytic leukemia management in a changing landscape

Symposium |Optimizing chronic lymphocytic leukemia management in a changing landscape

On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Lymphoma Hub Steering Committee mem...

20 Elo 23min

Symposium | BTK inhibitors in practice: Treatment selection and emerging clinical evidence

Symposium | BTK inhibitors in practice: Treatment selection and emerging clinical evidence

On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Farrukh Awan, University of Texas S...

12 Elo 27min

Symposium | BTK inhibitors in CLL: Mechanisms, clinical considerations, and unmet needs

Symposium | BTK inhibitors in CLL: Mechanisms, clinical considerations, and unmet needs

On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Lymphoma Hub Steering Committee mem...

12 Elo 12min

EHA 2026 | What are the key findings from the DALY 2-EU trial of zamto-cel in R/R LBCL?

EHA 2026 | What are the key findings from the DALY 2-EU trial of zamto-cel in R/R LBCL?

The Lymphoma Hub was pleased to speak with Gloria Iacoboni, Vall d'Hebron University Hospital, Barcelona, ES. We asked, What are the key findings from the DALY 2-EU trial of zamtocabtagene autoleucel ...

21 Heinä 8min

EHA2026 | What are the key findings from the subgroup analysis of the EPCORE FL-1 trial in R/R FL?

EHA2026 | What are the key findings from the subgroup analysis of the EPCORE FL-1 trial in R/R FL?

Following the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Lymphoma Hub spoke with Lorenzo Falchi, Memorial Sloan Kettering Cancer Center, New York, US. We...

16 Heinä 10min

Zanubrutinib for patients with previously untreated CLL/SLL: Insights from the SEQUOIA trial

Zanubrutinib for patients with previously untreated CLL/SLL: Insights from the SEQUOIA trial

During the Lymphoma Hub Steering Committee Meeting on April 20, 2026, key opinion leaders met to discuss results from the long-term follow-up of the phase III SEQUOIA trial (NCT03336333) evaluating za...

10 Heinä 26min

EHA 2026 | What are the key findings from the phase I ANTLER trial in R/R B-cell NHL?

EHA 2026 | What are the key findings from the phase I ANTLER trial in R/R B-cell NHL?

During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2025, Stockholm, SE, the Lymphoma Hub spoke with Stephen Schuster, University of Pennsylvania, Philadelphia, US. We asked, W...

1 Heinä 5min

Annual oncology meeting | Key highlights in lymphoma

Annual oncology meeting | Key highlights in lymphoma

During the American Society of Clinical Oncology Annual Meeting, May 19 – June 2, 2026, Chicago, US, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount ...

22 Kesä 11min

Suosittua kategoriassa Koulutus

rss-murhan-anatomia
psykopodiaa-podcast
aamukahvilla
adhd-podi
voi-hyvin-meditaatiot-2
rss-rahamania
rss-vapaudu-voimaasi
rss-niinku-asia-on
rss-liian-kuuma-peruna
rss-koira-haudattuna
rss-keskeneraiset-aidit
kesken
koulu-podcast-2
ihminen-tavattavissa-tommy-hellsten-instituutti
rss-uskonto-on-tylsaa
rss-arkea-ja-aurinkoa-podcast-espanjasta
rahapuhetta
puhutaan-koiraa
rss-varapare
rss-duodecim-lehti